200 related articles for article (PubMed ID: 12143054)
1. ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions.
Endo K; Yoon BI; Pairojkul C; Demetris AJ; Sirica AE
Hepatology; 2002 Aug; 36(2):439-50. PubMed ID: 12143054
[TBL] [Abstract][Full Text] [Related]
2. Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targets.
Sirica AE; Lai GH; Endo K; Zhang Z; Yoon BI
Semin Liver Dis; 2002 Aug; 22(3):303-13. PubMed ID: 12360423
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: A link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma.
Radaeva S; Ferreira-Gonzalez A; Sirica AE
Hepatology; 1999 May; 29(5):1453-62. PubMed ID: 10216129
[TBL] [Abstract][Full Text] [Related]
4. Expression of cyclooxygenase-1 and -2 in extra-hepatic cholangiocarcinoma.
Wu GS; Wang JH; Liu ZR; Zou SQ
Hepatobiliary Pancreat Dis Int; 2002 Aug; 1(3):429-33. PubMed ID: 14607721
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm.
Hayashi N; Yamamoto H; Hiraoka N; Dono K; Ito Y; Okami J; Kondo M; Nagano H; Umeshita K; Sakon M; Matsuura N; Nakamori S; Monden M
Hepatology; 2001 Oct; 34(4 Pt 1):638-50. PubMed ID: 11584358
[TBL] [Abstract][Full Text] [Related]
6. Expression of c-erbB-2 and cyclooxygenase-2 in intrahepatic cholangiocarcinoma.
Choi HJ; Kim HJ; Choi JH
Hepatogastroenterology; 2009; 56(91-92):606-9. PubMed ID: 19621664
[TBL] [Abstract][Full Text] [Related]
7. COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells.
Nzeako UC; Guicciardi ME; Yoon JH; Bronk SF; Gores GJ
Hepatology; 2002 Mar; 35(3):552-9. PubMed ID: 11870367
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis of cholangiocarcinoma in patients with PSC: a sight on cytology.
Baskin-Bey ES; Moreno Luna LE; Gores GJ
J Hepatol; 2006 Oct; 45(4):476-9. PubMed ID: 16901574
[No Abstract] [Full Text] [Related]
9. Clinicopathological correlates of aspartyl (asparaginyl) beta-hydroxylase over-expression in cholangiocarcinoma.
Maeda T; Taguchi K; Aishima S; Shimada M; Hintz D; Larusso N; Gores G; Tsuneyoshi M; Sugimachi K; Wands JR; de la Monte SM
Cancer Detect Prev; 2004; 28(5):313-8. PubMed ID: 15542253
[TBL] [Abstract][Full Text] [Related]
10. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice.
Farazi PA; Zeisberg M; Glickman J; Zhang Y; Kalluri R; DePinho RA
Cancer Res; 2006 Jul; 66(13):6622-7. PubMed ID: 16818635
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis.
Terada T; Nakanuma Y; Sirica AE
Hum Pathol; 1998 Feb; 29(2):175-80. PubMed ID: 9490278
[TBL] [Abstract][Full Text] [Related]
12. Expression of cyclooxygenase-2 in cholangiocarcinoma: correlation with clinicopathological features and prognosis.
Kim HJ; Lee KT; Kim EK; Sohn TS; Heo JS; Choi SH; Choi DI; Lee JK; Paik SW; Rhee JC
J Gastroenterol Hepatol; 2004 May; 19(5):582-8. PubMed ID: 15086604
[TBL] [Abstract][Full Text] [Related]
13. Significance of c-erbB-2 expression in normal and neoplastic epithelium of biliary tract.
Chow NH; Huang SM; Chan SH; Mo LR; Hwang MH; Su WC
Anticancer Res; 1995; 15(3):1055-9. PubMed ID: 7645925
[TBL] [Abstract][Full Text] [Related]
14. Different expression of cyclooxygenase-2 in biliary epithelia of bile duct cancer with or without pancreaticobiliary maljunction.
Watanabe O; Yoshimatsu K; Shiozawa S; Tsuchiya A; Oshibe N; Aiba M; Ogawa K
Anticancer Res; 2004; 24(2B):671-4. PubMed ID: 15161010
[TBL] [Abstract][Full Text] [Related]
15. Bile duct expression of pancreatic and duodenal homeobox 1 in perihilar cholangiocarcinogenesis.
Igarashi S; Matsubara T; Harada K; Ikeda H; Sato Y; Sasaki M; Matsui O; Nakanuma Y
Histopathology; 2012 Aug; 61(2):266-76. PubMed ID: 22594685
[TBL] [Abstract][Full Text] [Related]
16. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for overall survival in intrahepatic cholangiocarcinoma.
Schmitz KJ; Lang H; Wohlschlaeger J; Reis H; Sotiropoulos GC; Schmid KW; Baba HA
Virchows Arch; 2007 Feb; 450(2):135-41. PubMed ID: 17165088
[TBL] [Abstract][Full Text] [Related]
17. Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma.
Chariyalertsak S; Sirikulchayanonta V; Mayer D; Kopp-Schneider A; Fürstenberger G; Marks F; Müller-Decker K
Gut; 2001 Jan; 48(1):80-6. PubMed ID: 11115827
[TBL] [Abstract][Full Text] [Related]
18. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers.
Nakazawa K; Dobashi Y; Suzuki S; Fujii H; Takeda Y; Ooi A
J Pathol; 2005 Jul; 206(3):356-65. PubMed ID: 15892172
[TBL] [Abstract][Full Text] [Related]
19. Expression of c-erbB-2 proto-oncogene in extrahepatic cholangiocarcinoma and its clinical significance.
Zheng J; Zhu YM
Hepatobiliary Pancreat Dis Int; 2007 Aug; 6(4):412-5. PubMed ID: 17690040
[TBL] [Abstract][Full Text] [Related]
20. Primary sclerosing cholangitis and cholangiocarcinoma.
Lazaridis KN; Gores GJ
Semin Liver Dis; 2006 Feb; 26(1):42-51. PubMed ID: 16496232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
